CRISPR-TIL for metastatic melanoma

2023-510417-25-01 Protocol MM2318 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 6 Dec 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol MM2318

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 10
Countries 1
Sites 1

Advanced or metastatic melanoma

Key facts

Sponsor
Herlev Hospital
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
6 Dec 2024 → ongoing
Decision date (initial)
2024-09-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced or metastatic melanoma

VersionLevelCodeTermSystem organ class
21.1 PT 10025671 Malignant melanoma stage IV 100000004864
21.1 PT 10025670 Malignant melanoma stage III 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Herlev Hospital

Sponsor organisation
Herlev Hospital
Address
Borgmester Ib Juuls Vej 1
City
Herlev
Postcode
2730
Country
Denmark

Scientific contact point

Organisation
Herlev Hospital
Contact name
Joel Emanuel Jörn

Public contact point

Organisation
Herlev Hospital
Contact name
Joel Emanuel Jörn

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 10 1
Rest of world 0

Investigational sites

Denmark

1 site · Ongoing, recruiting
Herlev Hospital
Oncology, Borgmester Ib Juuls Vej 1, 2730, Herlev

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2024-12-06 2024-12-06

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-12 Denmark Acceptable
2024-09-16
2024-09-16